Ann: Chairman's Address to Shareholders , page-2

Quotes from address:


SALES:
The total sales revenue for the year was $8,497,803, an increase of 9.5% on last year’s figure ($7,775,568).

PROFIT:
The profit for the year was a record $1,249,961. This compares with $1,022,497. So, it is fair to say that we are very pleased with the result, especially as the results were due to a general improvement in both segments of the business rather that as the results on any one-off event.

DIVIDEND:
Following on from our maiden payment last year, this year we have paid a total dividend of 1.5 cents per share.

Cash at 31 October was $5,644,222.

Biological services include the private cord blood service, adult stem cell storage and biorepository management.

In May 2012 Cryosite became the first private cord blood service to have TGA approval for the directed allogenic release of cord blood.

Whilst this licence status is now not exclusive to Cryosite, we have continued to maintain a steady increase in cord blood storage clients.

Last year I mentioned that we had entered into a collaboration with Regeneus (ASX:RGS).

This is good news for Cryosite as we will receive a steady stream of samples for cryopreservation and release for treatment.

The warehousing and distribution service continued to perform extremely well, particularly the clinical trial logistics service. We now have in excess of 400 active trials under management.